Pacira Pharmaceuticals announced that Exparel (bupivacaine liposome injectable suspension) is now commercially available. Exparel was approved by the FDA in October 2011 for single-dose infiltration into the surgical site to produce postsurgical analgesia. Exparel, a multivesicular, non-opioid, liposome, local anesthetic combines bupivacaine with DepoFoam, a product delivery technology that releases medication over a desired period of time.
Exparel is available from Pacira as a 1.3% dosage strength suspension in 10mL and 20mL single use vials.
For more information call (973) 254-3560 or visit www.exparel.com.